Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Senores Pharmaceuticals Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹391
Per ShareLot Size
38 Shares
Minimum Investment
₹14,858
Issue Size
₹582.11 Cr
Face Value
₹10
Per ShareIPO Type
Book Building
Retail Quota
10%
QIB Quota
75%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
66.66%
Promoter Holding (Post-Issue)
45.76%
Issue Type
Book Building
ISIN
INE0RB801010
We are a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms. Our Regulated Markets business is primarily focused on the Regulated Markets of US, Canada, and United Kingdom. We have adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and as of March 31, 2024, we have received approvals for 19 ANDAs. We develop and manufacture generic pharmaceutical products across various therapeutic areas for the Emerging Markets in the B2B segment, having a presence across 43 countries. We also operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.
As per the F&S Report, the US pharmaceutical market increased from USD 589.0 billion in CY 2021 to USD 711.0 billion in CY 2023. The US CDMO market grew from USD 36.3 billion in CY 2021 to USD 44.7 billion in CY 2023. The Emerging pharmaceutical market rose from USD 354.3 billion in CY 2021 to USD 376.3 billion in CY 2023. The Indian hospital channel market expanded from USD 3.9-4.7 billion in CY 2021 to USD 4.7-5.7 billion in CY 2023 while the India API market increased from USD 11.5 billion to USD 13.1 billion in the same period.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 14,887,723 equity shares of face value of Rs. 10 each ("Equity Shares") of Senores Pharmaceuticals Limited ("The Company" or the "Issuer") for cash at a price of Rs. 391 per equity share (including a share premium of Rs. 381 per equity share) ("Offer Price") aggregating to Rs. 582.11 crores (the "Offer"). The offer comprises of a fresh issue of 12,787,723 equity shares by the company aggregating to Rs. 500.00 crores (the "Fresh Issue") and an offer for sale of 2,100,000 equity shares (the "Offered Shares") aggregating to Rs. 82.11 crores (the "Offer for Sale"), comprising 250,000 equity shares aggregating to Rs. 9.78 crores by Swapnil Jatinbhai Shah, 550,000 equity shares aggregating to Rs. 21.51 crores by Ashokkumar Vijaysinh Barot, 300,000 equity shares aggregating to Rs. 11.73 crores by Sangeeta Mukur Barot and 1,000,000 equity shares aggregating to Rs. 39.10 crores by Prakash M Sanghvi (the "Selling Shareholders"). The offer shall constitute 32.33 % of the post-offer paid-up equity share capital of the company. The offer includes a reservation of 75,000 equity shares, aggregating to Rs. 2.93 crores constituting 0.16% of the post-offer paid-up equity share capital, for subscription by eligible employees ("Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The face value of the equity shares is Rs. 10 each and the offer price is 39.10 times the face value of the equity shares.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through a certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023 and a special resolution passed in the general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY23 to FY25.